The influence of comorbidities on mortality in sarcoidosis: A observational prospective cohort study

Abstract Aim: The aim of this study was to identify the frequency and prevalence of comorbidities in sarcoid patients and to assess their influence on overall mortality in the cohort of patients with sarcoidosis. Materials and methods: A cohort of 557 patients with histologically confirmed sarcoidosis diagnosed between 2007 and 2011 and a group of non sarcoid controls were observed. All patients were carefully observed for comorbidities and mortality. Results: 291 males (52.2%) and 266 females (47.8%) with mean age 48,4 ±12,0 yrs in sarcoidosis group and a group of 100 controls with mean age (49.25±10.3) were observed. The mean number of comorbidities in both groups was similar (0.9 ±0.99 vs 0.81±0.84 NS). The frequency of thyroid disease was significantly higher in sarcoidosis group comparing to controls at the time of diagnosis (OR =3.62 p=0.0144). During the observation period (median 58.0 months) 16 patients died (2.9%). The mean number of comorbidities was significantly higher in the groups of non‐survivors as compared to survivors, (2.8 ±1.0, vs 0.8 ±0.9) p 
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research

Related Links:

AbstractPurposeReduced physical activity in many chronic diseases is consistently associated with increased morbidity. Little is known about physical activity in sarcoidosis. The aim of this study was to objectively assess physical activity in patients with pulmonary sarcoidosis and investigate its relationship with lung function, exercise capacity, symptom burden, and health status.MethodsPhysical activity was assessed over one week in 15 patients with pulmonary sarcoidosis and 14 age-matched healthy controls with a tri-axial accelerometer (ActivPal ™) and the International Physical Activity Questionnaire (IPAQ). Al...
Source: Lung - Category: Respiratory Medicine Source Type: research
ConclusionsThe algorithm involving CHITO, hs-CRP, and ACE could be a suitable strategy for differentiation between sarcoidosis activity/remission status.
Source: Lung - Category: Respiratory Medicine Source Type: research
ConclusionEPS may help with risk stratification in patients with CS and abnormal imaging, especially those without conventional indications for ICD placement. Among patients with LVEF>35% and no history of prior VA, a negative EPS has good positive and negative predictive value for future VA events.
Source: IJC Heart and Vasculature - Category: Cardiology Source Type: research
Authors: Boutagy NE, Feher A, Alkhalil I, Umoh N, Sinusas AJ Abstract Multimodality cardiovascular imaging is routinely used to assess cardiac function, structure, and physiological parameters to facilitate the diagnosis, characterization, and phenotyping of numerous cardiovascular diseases (CVD), as well as allows for risk stratification and guidance in medical therapy decision-making. Although useful, these imaging strategies are unable to assess the underlying cellular and molecular processes that modulate pathophysiological changes. Over the last decade, there have been great advancements in imaging instrumenta...
Source: Comprehensive Physiology - Category: Physiology Tags: Compr Physiol Source Type: research
Authors: Toussirot E, Bernard C, Bossert M Abstract PMID: 30873944 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
We present a series of patients with sarcoidosis associated PH and describe correlation between the pre-transplant hemodynamic data from a right heart catheterization (RHC) and vascular morphologic changes in the native explanted lungs.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 117 Source Type: research
Clinical findings of cardiac sarcoidosis are evident in only about 5% of patients with sarcoidosis however approximately 20% of autopsies demonstrate myocardial involvement. The epidemiology and prognosis of cardiac sarcoidosis remains poorly understood.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 488 Source Type: research
Cardiac sarcoidosis is a potentially reversible etiology of heart failure if identified and managed in a timely fashion. Given the multisystem nature of the disease and need for a high index of suspicion, diagnosis of cardiac sarcoidosis is difficult, and the underlying cause remains speculative.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 487 Source Type: research
To investigate outcome of patients with giant cell myocarditis (GCM) or cardiac sarcoidosis (CS) who undergo heart transplantation (HTx) or implantation of mechanical circulatory support (MCS).
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 723 Source Type: research
we recently read with interest the case series on the novel disease entity of combined sarcoidosis and idiopathic pulmonary fibrosis (IPF/UIP) identified by Raghu et al. and defined as CSIPF (1). The association of these interstitial lung diseases (ILD) with different ethiopathogenesis and clinical course in a single patient is a real rare event, and the above description of 25 patients raises the question whether this association represents a mere coincidence or a novel phenotype consequent to a genetic undefined mutation.
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Tags: Correspondence Source Type: research
More News: Respiratory Medicine | Sarcoidosis | Study | Thyroid